CRISPR Therapeutics and Vertex Pharmaceuticals unveiled early data from the first company-backed study to test a CRISPR-based medicine in humans. The data, from two patients with severe blood ...
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders—sickle-cell disease (SCD) and beta ...
Vertex Pharmaceuticals (NASDAQ: VRTX) and its partner, CRISPR Therapeutics (NASDAQ: CRSP), have achieved significant progress with their drug targeting rare blood diseases beta thalassemia and sickle ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is taking ...
Bears Vertex is highly dependent on the success of its cystic fibrosis franchise, and it could fail to diversify if its other pipeline candidates are not successful. Pricing pressure could erode ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Vertex Pharmaceuticals has two clinical-stage programs for type 1 diabetes, each employing different methods for preventing the immune system from rejecting the cell therapies. For a third program in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback